Loading... (0%)
About liver disease

GENFIT: A GLOBAL APPROACH TO THE DISEASE

Facilitate identification and referrals of NASH patients.
LEARN MORE
Phase 3 study of elafibranor in NASH with fibrosis is currently enrolling patients around the world.
LEARN MORE

COMPANY LIFE

GENFIT is a biopharmaceutical company dedicated to high unmet medical needs.
Learn more
Find out our about current job opportunities or submit your spontaneous application explaining your project.
LEARN MORE

DOCUMENTATION

The NASH Education Program™

Health prevention, medical education, dissemination of relevant information related to NASH disease

ACCESS THE NASH EDUCATION PROGRAM™ WEBSITE
Press releases
  • GENFIT: Major Milestone for the RESOLVE-IT Phase 3 Trial on the Recruitment of the Interim Analysis Cohort
    04/11/2018
  • GENFIT: Presentations at EASL 2018 Annual Congress Highlight Progress in NASH Diagnostics, Combination Therapies and Deep-learning Applications in Medical Imaging
    03/28/2018
  • GENFIT: Official Launch of the NASH Pediatric Program, following PIP and PSP Agreement by EMA and FDA
    01/23/2018
  • GENFIT: Contributing Significantly to the European LITMUS Initiative on NASH Biomarkers
    11/27/2017
694a42221e9afe622a2ab171124ce39c""""""""""